Arsenic trioxide as a treatment for myelodysplastic syndrome.

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous bone marrow disorder primarily affecting older adults, for whom the only curative therapy, bone marrow transplantation, is rarely an option. New therapies, or novel applications of historical therapies, are desperately needed. Arsenic trioxide (ATO), which acts through proapoptotic, antiproliferative, and antiangiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. As monotherapy or in combination with other agents, it can effect hematologic improvement in 22% to 26% of patients, with tolerable side effects. MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy.

• Authors: Mikkael A Sekeres
• Journal: Current hematologic malignancy reports (Curr Hematol Malig Rep) Vol. 1 Issue 1 Pg. 34-8 (Mar 2006) ISSN: 1558-822X [Electronic] United States
• PMID: 20425329 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Antineoplastic Agents
• Arsenicals
• DNA-Binding Proteins
• MDS1 and EVI1 Complex Locus Protein
• MECOM protein, human
• Oxides
• Transcription Factors
• Thalidomide
• Arsenic Trioxide

Topics

• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Apoptosis (drug effects)
• Arsenic Trioxide
• Arsenicals (administration & dosage, pharmacology, therapeutic use)
• Clinical Trials as Topic
• DNA-Binding Proteins (genetics)
• Drug Therapy, Combination
• Humans
• Leukemia, Promyelocytic, Acute (drug therapy)
• MDS1 and EVI1 Complex Locus Protein
• Multicenter Studies as Topic
• Myelodysplastic Syndromes (drug therapy, genetics)
• Oxides (administration & dosage, pharmacology, therapeutic use)
• Proto-Oncogenes (genetics)
• Salvage Therapy
• Thalidomide (administration & dosage, therapeutic use)
• Transcription Factors (genetics)